MAPT and Alzheimer disease: The attenuation of the treatment effects of HMT by chronic pre‐treatment with drugs that offer symptomatic benefit was recapitulated in tau transgenic mice as a result of homeostatic down‐regulation of multiple neuronal systems in response to the sustained hyperactivation generated by treatment with standard symptomatic drugs for AD [32, 33].